Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Condition:   Ductal Carcinoma in SituIntervention:   Drug: SOM 230 / PasireotideSponsor:   New York University School of MedicineRecruiting - verified April 2015

Source: ClinicalTrials.gov - June 9, 2011 Category: Research Source Type: clinical trials